Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

St. Luke's unveils Discovery IGS 730 Hybrid OR from GE Healthcare

St. Luke's University Hospital unveiled the Discovery IGS 730 Hybrid OR from GE Healthcare today, becoming the first hospital in the United States to offer this exciting new technology.

17 Nov 2012

BeamPath ROBOTIC system from OmniGuide used in Laparoscopic Myomectomy

Antonio R. Gargiulo, MD of the Center for Infertility and Reproductive Surgery at Brigham and Women's Hospital completed a live surgery for the American Society of Reproductive Medicine, treating a patient suffering from uterine fibroids with a novel robotic surgical approach and a cutting edge laser technology developed at OmniGuide in Cambridge, MA.

3 Nov 2012

Alternate method to precisely tag breast cancer tumors

When surgeons operate to remove a tumor, determining exactly where to cut can be tricky. Ideally, the entire tumor should be removed while leaving a continuous layer of healthy tissue, but current techniques for locating the tumors during surgery are imprecise. Now a multidisciplinary team from the University of California, San Diego, is developing an alternate means of precisely tagging breast cancer tumors for removal or targeted destruction.

29 Oct 2012

Focused ultrasound technology safe, effective in treating patients with tremor-dominant Parkinson's

The Focused Ultrasound Foundation today announced a new clinical trial investigating the use of focused ultrasound technology in treating patients with tremor-dominant Parkinson's disease.

25 Oct 2012

Genetic basis of uterine fibroids uncovered

A mutation located near the fatty acid synthase gene is associated with an increased predisposition for uterine leiomyomata or fibroids, suggest US study findings.

8 Oct 2012

Researchers identify genetic risk allele for uterine fibroids

Uterine fibroids are the most common type of pelvic tumors in women and are the leading cause of hysterectomy in the United States. Researchers from Brigham and Women's Hospital (BWH) are the first to discover a genetic risk allele (an alternative form of a gene) for uterine fibroids in white women using an unbiased, genome-wide approach.

5 Oct 2012

Prenatal exposure to BPA appears to program uterine estrogen responsiveness in adulthood

Prenatal exposure to bisphenol A, or BPA, a chemical found in many common plastic household items, can cause numerous genes in the uterus to respond differently to estrogen in adulthood, according to a study using a mouse model. The results will be presented Tuesday at The Endocrine Society's 94th Annual Meeting in Houston.

27 Jun 2012

Abbott commences elagolix Phase 3 trial in endometriosis

Abbott, in cooperation with Neurocrine Biosciences, Inc., today announced the initiation of a pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis.

6 Jun 2012

Urocortin 2 improves cardiac output in Phase II study for acute decompensated heart failure

Neurocrine Biosciences, Inc. today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure. The UNICORN study was conducted over approximately a two year period by the Cardioendocrine Research Group from the University of Otago in Christchurch, New Zealand and included patients admitted to Christchurch Hospital with acute decompensated heart failure.

18 May 2012

Hologic features minimally invasive technologies at ACOG annual clinical meeting

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, is featuring minimally invasive technologies in surgical, diagnostic and skeletal health at The American College of Obstetricians and Gynecologists (ACOG) annual clinical meeting.

From Hologic, Inc. 7 May 2012

Hologic second quarter revenues increase 7.4% to $471.2 million

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced its results for the second fiscal quarter ended March 24, 2012.

From Hologic, Inc. 30 Apr 2012

Hologic enters definitive agreement to acquire Gen-Probe

Hologic, Inc. and Gen-Probe Incorporated today announced that their Boards of Directors have unanimously approved a definitive agreement under which Hologic will acquire all of the outstanding shares of Gen-Probe for $82.75 per share in cash, or a total enterprise value of approximately $3.7 billion.

From Hologic, Inc. 30 Apr 2012

New embolization procedure may bring hope to men with enlarged prostate

A new interventional radiology treatment, prostatic artery embolization, may bring hope to men with debilitating symptoms caused by an enlarged prostate, say the group of researchers who pioneered its use.

26 Mar 2012

Watson commences Esmya Phase 3 trial in women with anemia linked to uterine leiomyomas

Watson Pharmaceuticals, Inc. today announced it has initiated its Phase 3 trial to evaluate the efficacy and safety of Esmya (ulipristal acetate) in women with anemia associated with uterine leiomyomas, a medical condition often referred to as uterine fibroids (myomas). Leiomyomata are benign solid tumors that often lead to excessive menstrual bleeding, anemia and pain, which ultimately may require surgical intervention.

12 Mar 2012

Treatment with vitamin D reduces size of uterine fibroids

Treatment with vitamin D reduced the size of uterine fibroids in laboratory rats predisposed to developing the benign tumors, reported researchers funded by the National Institutes of Health.

2 Mar 2012

Hologic first quarter revenues increase 9.3% to $472.7 million

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced its results for the first fiscal quarter ended December 24, 2011.

From Hologic, Inc. 31 Jan 2012

InSightec seeks FDA premarket approval for ExAblate treatment of pain palliation of bone metastases

InSightec Ltd, the leader in MR guided Focused Ultrasound therapy, announced that it has submitted a premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for its ExAblate treatment of pain palliation of bone metastases.

24 Jan 2012

BU professor to study incidence of hypertension, diabetes and asthma in African American women

Patricia F. Coogan, ScD, an associate professor of epidemiology at Boston University's Slone Epidemiology Center (SEC), recently was awarded funding for two grants from the National Institutes of Health.

21 Dec 2011

Hologic receives FDA approval for Cervista HTA system to detect cervical cancer

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that the U.S. Food and Drug Administration (FDA) has approved its Cervista HTA (high throughput automation) system for use with the Company's previously approved Cervista human papillomavirus (HPV) HR test.

From Hologic, Inc. 16 Dec 2011

Mayo Clinic becomes FUS Foundation's new Research Award recipient

The Focused Ultrasound Surgery Foundation has announced that its Research Awards Program is funding a Mayo Clinic study that will be the first to use U.S. commercial database information to compare the costs of three minimally-invasive treatments for symptomatic uterine fibroids, a benign and often debilitating condition that affects more than one in four American women.

30 Nov 2011